Periodic assessment of tumor marker levels (carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9)) and enhanced computed tomography (CT) were performed during follow-up. This evidence concerns the gene CEACAM5 and neoplasm.